1、CORPORATE GOVERNANCEREPORT2024Novo Nordisk A/S Novo Alle 1,2880 Bagsvrd,Denmark CVR no.24256790A Novo Nordisk employee receiving a tour of our active construction project at our site in Kalundborg,Denmark.This project is part of our investment of more than DKK 80 billion in new active pharmaceutical

2、 ingredient facilities.These significant expansions aim to scale up production of life-changing treatments,including GLP-1-based medicines,to benefit many more people living with serious chronic diseases.2Corporate Governance Report /Content1.Introduction 32.Corporate governance recommendations and

3、practices 33.Novo Nordisk governance structure 44.Board of Directors 45.Board committees 56.Executive Management 97.Risk management 98.Internal control 10Appendix 1 Novo Nordisks reporting on the Danish Corporate Governance Recommendations 12Appendix 2 Novo Nordisks reporting on the Corporate Govern

4、ance Standards of the New York Stock Exchange 25Content3Corporate Governance Report /The financial year 2024Corporate Governance Report for the financial year 20241.In Danish“Redegrelse for virksomhedsledelse,jf.rsregnskabslovens 107 b”2.The Danish Corporate Governance Recommendations are available

5、at:https:/corporategovernance.dk/gaeldende-anbefalinger-god-selskabsledelse3.The Corporate Governance Standards as included in the NYSE Listed Company Manual are available at:https:/nyse.wolterskluwer.cloud/listed-company-manual1.IntroductionThis Corporate Governance Report for Novo Nordisk A/S(Novo

6、 Nordisk or the Company),including appendices,for the financial year 2024(the Report)is prepared pursuant to Section 107 b of the Danish Financial Statements Act1 and forms part of the Annual review of the statutory Annual Report 2024.Sections 3-8(“Novo Nordisk governance structure”,“Board of Direct